Is this Seattle Penny Pot Stock a Potential Blockbuster?
A small, rapidly expanding Seattle cannabis company is gaining attention from investors. Founded by two cannabis veterans, the company has increased sales 8-fold and is looking to double sales again in the next two years. Now selling for less than $1 per share, this is an opportunity to acquire thousands of shares – a potential windfall.
Get Free Report on #1 Cannabis Pick for 2021

REDX Insider Trading (Redx Pharma)

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): £19,999
Insider Selling (Last 12 Months): GBX 0

Redx Pharma Insider Trading History Chart

Redx Pharma Share Price & Price History

GBX 60.13
▼ -2.375 (-3.80%)
As of 06/22/2021 04:04 PM ET
Days: 30 | 90 | 365
Is this Seattle Penny Pot Stock a Potential Blockbuster?
A small, rapidly expanding Seattle cannabis company is gaining attention from investors. Founded by two cannabis veterans, the company has increased sales 8-fold and is looking to double sales again in the next two years. Now selling for less than $1 per share, this is an opportunity to acquire thousands of shares – a potential windfall.
Get Free Report on #1 Cannabis Pick for 2021

Redx Pharma Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/22/2020Lisa AnsonInsiderBuy39,998GBX 50£19,999
See Full Table
Redx Pharma logo
Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating anti-cancer and fibrosis targets in the areas of unmet medical needs. The company is developing RXC004, a porcupine inhibitor, which has completed Phase I clinical development for the treatment of colorectal, pancreatic, biliary, and gastric cancers, as well as melanoma; ROCK inhibitor for treating inflammatory intestinal fibrosis; RXC007, a Rho-associated protein kinase 2 inhibitors for the treatment of orphan disease, idiopathic pulmonary fibrosis, non-alcoholic steatohepatitis, and other systemic fibrotic conditions; and Porcupine (RXC006), which is in Phase I for the treatment of lung fibrosis. Redx Pharma Plc has a research collaboration agreement with Jazz Pharmaceuticals plc to discover and develop drug candidates for two cancer targets in the Ras/Raf/MAP kinase pathway. The company was founded in 2010 and is based in Macclesfield, the United Kingdom.
Read More on Redx Pharma

Today's Range

Now: GBX 60.13
60.13
61.75

50 Day Range

MA: GBX 64.14
57.40
68.75

52 Week Range

Now: GBX 60.13
15.05
95

Volume

5,621 shs

Average Volume

22,585 shs

Market Capitalization

£164.67 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Redx Pharma?

Redx Pharma's top insider investors include:
  1. Lisa Anson (Insider)
Invest In Psychedelic Therapy?
Psychedelic Therapy Clinics are popping up all over LA and Arizona. Some of them charge up to $2,000 for a full treatment... this is an emerging trend every investor should consider.
Tell Me More About Psychedelic Therapy